Search clinical trials for: E1M184V peptide vaccine

Total 8178 results

Gitte Kronborg
Rigshospitalet, Denmark; Hvidovre University Hospital; Statens Serum Institut; Ministry...

Completed

Immunization With HIV-1 Peptides in Adjuvant for Treatment of Patients With Chronic HIV-infection (HIV-VAC)

HIV INFECTIONS

Denmark
National Liver Institute, Egypt

Unknown

Safety and Efficacy Study of CENV3 Vaccine to Protect Against HCV Infection (CENV3)

Vaccine Overdose of Undetermined Intent

Egypt
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant

Hematopoietic and Lymphoid Cell Neoplasm | Hodgkin Lymphoma | Myelofibrosis | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Myelodysplastic/Myeloproliferative Neoplasm | Acute Myeloid Leukemia in Remission | Acute Lymphoblastic Leukemia in Remission | Cytomegalovirus... and other conditions

United States
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Vaccine Therapy, Incomplete Freund's Adjuvant, and GM-CSF in Treating Patients With HIV

Nonneoplastic Condition

United States
National Cancer Institute (NCI)

Completed

Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery

Stage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant

Hematopoietic Cell Transplant Recipient | Cytomegaloviral Infection

United States
University of Washington
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab

Stage IV Breast Cancer | HER2/Neu Positive | HLA-A2 Positive Cells Present | Stage IV Ovarian Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Preventing Cytomegalovirus in Healthy Participants

Nonneoplastic Condition

United States
United Biomedical

Completed

A Phase I/II Safety and Immunogenicity Trial of UBI Microparticulate Monovalent (HIV-1 MN) Branched Peptide Vaccine in HIV-1 Seronegative Human Subjects

HIV Infections

United States
M.D. Anderson Cancer Center
The Vaccine Company

Terminated

PR1 Vaccination in Myelodysplastic Syndrome (MDS)

Leukemia | Myelodysplastic Syndrome

United States
University of Maryland Greenebaum Cancer Center
National Cancer Institute (NCI)

Completed

Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma

Multiple Myeloma and Plasma Cell Neoplasm

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
COL George Peoples, MD, FACS

Completed

Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer

Ovarian Cancer | Endometrial Cancer | Peritoneal Cancer | Fallopian Cancer

United States
Michael Morse, MD
Immunotope

Completed

A Phase I Study of Ovarian Cancer Peptides Plus GM-CSF and Adjuvant With Ovarian, Tubal or Peritoneal Cancer

Epithelial Ovarian, Tubal or Peritoneal Cancer

United States
University of California, Davis
National Cancer Institute (NCI); IO Biotech

Recruiting

IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

Stage 0a Bladder Cancer AJCC v8 | Stage 0is Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8 | High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI); Diavax Biosciences

Active, not recruiting

Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant

Hodgkin Lymphoma | Myelofibrosis | Lymphoblastic Lymphoma | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Lymphadenopathy | Myeloproliferative Neoplasm | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Acute Myeloid Leukemia in Remission | Accelerated Phase... and other conditions

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Wilm's Tumor 1 (WT1) Peptide Vaccine for High Risk Hematologic Malignancy

Myelodysplastic Syndrome | Acute Myeloid Leukemia (AML) | Chronic Myeloid Leukemia (CML)

United States
University Hospital Tuebingen

Not yet recruiting

Multi-peptide Vaccination Adjuvanted With XS15 in Acute Myeloid Leukemia Patients (AML-VAC-XS15)

Acute Myeloid Leukemia, Adult
COL George Peoples, MD, FACS
M.D. Anderson Cancer Center

Completed

Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients (J65)

Breast Cancer | Ovarian Cancer

United States
African Malaria Network Trust
London School of Hygiene and Tropical Medicine

Unknown

Phase Ib Trial of MSP3 LSP in Children in Tanzania (MSP3TN)

Malaria

Tanzania
African Malaria Network Trust
London School of Hygiene and Tropical Medicine

Unknown

A Phase Ib Trial of MSP 3 LSP in 1-2 Year Old Children in Burkina Faso (MSP3LSP)

Malaria

Burkina Faso
University of Virginia
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Melanoma (Skin)

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...

Recruiting

Prophylactic Peptide Vaccine in Advanced ALK+ NSCLC

NSCLC Stage IV | ALK Fusion Protein Expression

United States
Inge Marie Svane

Recruiting

Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma

Metastatic Melanoma

Denmark
H. Lee Moffitt Cancer Center and Research Institute
National Institutes of Health (NIH)

Completed

PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment

Prostate Cancer

United States, Puerto Rico
zeinab ahmed yousif hasan ashour

Recruiting

Personalized Cancer Vaccine in Egyptian Cancer Patients (PROVE)

Hepatocellular Carcinoma

Egypt
Herbert Lyerly

Recruiting

Cancer Peptides Plus GM-CSF and Adjuvant in Breast Cancer

Breast Cancer

United States
University Hospital Tuebingen
Cooperative Weichteilsarkom Study Group; Deutsches Konsortium fürTranslationale... and other collaborators

Recruiting

Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision) (PerVision)

Ewing Sarcoma | Rhabdomyosarcoma | Synovial Sarcoma

Germany
Sellas Life Sciences Group

Completed

WT-1 Analog Peptide Vaccine in Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer

Breast Cancer

United States
Nina Bhardwaj

Completed

Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies

Solid Tumors

United States
Hadassah Medical Organization
Vaxil Therapeutics Ltd.

Withdrawn

A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies

Multiple Myeloma | Tumors

Israel
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Trial To Evaluate the Safety and Immunogenicity of the UBI HIV-1MN PND Peptide Immunogen, Given by IM Injection, in Combination With the UBI Microparticulate Monovalent HIV-1 MN Branched Peptide Given Orally, in HIV-1 Uninfected Volunteers.

HIV Infections

United States
Lene Meldgaard Knudsen

Completed

Vaccination With PD-L1 Peptide Against Multiple Myeloma

Multiple Myeloma

Denmark
Frank Lieberman
Oncovir, Inc.

Completed

Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas

Malignant Glioma

United States
San Antonio Military Medical Center
NuGenerex Immuno-Oncology; Norwell, Inc.

Completed

Vaccine Therapy in Treating Patients With Breast Cancer

Breast Cancer

United States, Germany, Greece
Kinki University
Human Genome Center, Institute of Medical Science, University of Tokyo

Completed

Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Gastric Cancer

Gastric Cancer

Japan
Emory University
Children's Healthcare of Atlanta

Withdrawn

Effects of Nesiritide in Pediatric Patients With Heart Failure

Heart Failure | Ventricular Dysfunction | Heart Decompensation
National Cancer Institute (NCI)

Completed

SGN-00101 Vaccine in Treating Human Papillomavirus in Patients Who Have Abnormal Cervical Cells

Cervical Cancer | High-grade Squamous Intraepithelial Lesion | Atypical Squamous Cells of Undetermined Significance | Low-grade Squamous Intraepithelial Lesion

United States
Ludwig Institute for Cancer Research
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Safety of Peptide Vaccination for Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome (MDS)

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Cytomegalovirus Vaccine in Healthy Participants

Precancerous/Nonmalignant Condition

United States
National Cancer Institute (NCI)

Terminated

Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer)

Recurrent Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States
National Center for Tumor Diseases, Heidelberg
German Cancer Research Center; University Hospital Heidelberg; Neuro-Oncology...

Completed

Phase I Trial of IDH1 Peptide Vaccine in IDH1R132H-mutated Grade III-IV Gliomas (NOA-16)

Glioma

Germany
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

HER-2 Protein Vaccine in Treating Women With Breast Cancer

Breast Cancer

United States
Jaime Leandro Foundation for Therapeutic Cancer...

Enrolling by invitation

Basket Trial of Neoantigen Synthetic Long Peptide Vaccines in Patients With Advanced Malignancy

Cancer | Solid Tumor

United States
National Cancer Institute (NCI)

Terminated

Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer

Melanoma | Breast Cancer | Pancreatic Cancer | Ovarian Cancer | Gastrointestinal Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia

Leukemia

United States
Robert Ferris
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients With Head and Neck Cancer

Head and Neck Cancer

United States
Craig L Slingluff, Jr
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma

Melanoma (Skin)

United States

Search clinical trials for: E1M184V peptide vaccine

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo, DR of

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations